Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Abern

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|April 20, 2012
Prostate cancer treatment unblindedMatvey Tsivian, Michael R Abern, Thomas J Polascik
Oncology (Williston Park, N.Y.)|March 7, 2013
Evolution of the concept of focal therapy for prostate cancerMatvey Tsivian, Michael R Abern, Thomas J Polascik
Current Urology Reports|February 3, 2012
Focal therapy of prostate cancer: evidence-based analysis for modern selection criteriaMichael R Abern, Matvey Tsivian, Thomas J Polascik
European Urology Focus|May 10, 2022
Genomic Sequencing Should Not be Part of the Standard of Care for Most Urologic CancersMichael R Abern, John V Dudinec, Brant A Inman
BJU International|April 24, 2012
C-reactive protein as a prognostic marker FOR mCRPCMichael R Abern, Emma H Allott, Stephen J Freedland
Urology|March 30, 2022
Prostate Cancer Disparities in Hispanics Using the National Cancer DatabaseMatthew Del Pino, Michael R Abern, Daniel M Moreira
Current Urology Reports|October 30, 2009
Penile shortening after radical prostatectomy and Peyronie's surgeryJonas S Benson, Michael R Abern, Laurence A Levine
Urologic Oncology|September 28, 2010
Marital status independently predicts testis cancer survival--an analysis of the SEER databaseMichael R Abern, Annie M Dude, Christopher L Coogan
The Journal of Urology|October 31, 2006
Persistent motile sperm after ligation band vasectomyLaurence A Levine, Michael R Abern, Matthew M Lux
The Journal of Sexual Medicine|September 29, 2011
Predicting erectile dysfunction following surgical correction of Peyronie's disease without inflatable penile prosthesis placement: vascular assessment and preoperative risk factorsFrederick L Taylor, Michael R Abern, Laurence A Levine
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|April 20, 2012
Prostate cancer treatment unblindedMatvey Tsivian, Michael R Abern, Thomas J Polascik
Oncology (Williston Park, N.Y.)|March 7, 2013
Evolution of the concept of focal therapy for prostate cancerMatvey Tsivian, Michael R Abern, Thomas J Polascik
Current Urology Reports|February 3, 2012
Focal therapy of prostate cancer: evidence-based analysis for modern selection criteriaMichael R Abern, Matvey Tsivian, Thomas J Polascik
European Urology Focus|May 10, 2022
Genomic Sequencing Should Not be Part of the Standard of Care for Most Urologic CancersMichael R Abern, John V Dudinec, Brant A Inman
BJU International|April 24, 2012
C-reactive protein as a prognostic marker FOR mCRPCMichael R Abern, Emma H Allott, Stephen J Freedland
Urology|March 30, 2022
Prostate Cancer Disparities in Hispanics Using the National Cancer DatabaseMatthew Del Pino, Michael R Abern, Daniel M Moreira
Current Urology Reports|October 30, 2009
Penile shortening after radical prostatectomy and Peyronie's surgeryJonas S Benson, Michael R Abern, Laurence A Levine
Urologic Oncology|September 28, 2010
Marital status independently predicts testis cancer survival--an analysis of the SEER databaseMichael R Abern, Annie M Dude, Christopher L Coogan
The Journal of Urology|October 31, 2006
Persistent motile sperm after ligation band vasectomyLaurence A Levine, Michael R Abern, Matthew M Lux
The Journal of Sexual Medicine|September 29, 2011
Predicting erectile dysfunction following surgical correction of Peyronie's disease without inflatable penile prosthesis placement: vascular assessment and preoperative risk factorsFrederick L Taylor, Michael R Abern, Laurence A Levine
Pageof 9